MedTech does not build value the way software does, and mistaking one for the other is an expensive error. This piece is about the difference and about reading the signals that arrive years before the obvious ones.

A slope and a staircase

A software company's value climbs a relatively smooth slope, each month a little higher than the last. A MedTech company's value climbs a staircase. Long flat treads where the work is happening invisibly, evidence accumulating, a submission in review, a coverage case being built, punctuated by sharp risers where a milestone lands and the company is suddenly worth far more than it was the day before. A clearance is a riser. A coverage decision is a riser. A pivotal read-out is a riser.

Once you see the staircase, a common error becomes obvious. Judging a MedTech company only by what is already visible means reading the flat tread and missing the riser that is coming. The interesting information is not in the lagging metric. It is in the events that will produce it, and those events cast shadows in advance if you know what to look for.

Read the leading indicators

Because the inflection is gated by events, the events are legible ahead of time. A clean regulatory path, chosen deliberately, with the predicate logic and strategy already clear.

Reimbursement designed in from day one rather than discovered at launch, with a payable service identified and the evidence plan underway. A data flywheel that genuinely compounds, so the product improves with use rather than aging in place. Real clinicians pull; the earliest and truest demand signal a medical product has. And capital efficiency you can model, so the company reaches the next milestone without betting its life on a perfect market.

None of these is revenue. All of them are the leading edge of the revenue that is coming, and together they describe where a company actually sits on the staircase. The discipline of reading them is harder than waiting for the lagging number, but it is also where the real understanding lives.

Clinician pull is the earliest signal

The single most underrated leading indicator in MedTech is clinician pull, underrated precisely because it does not look like revenue. When the people who would actually use a product are asking for it, designing their practice around the prospect of it, volunteering to run the studies that prove it, that is demand expressed before a payment mechanism exists to convert it into revenue.

In a field where adoption is the hardest part, demonstrated pull from credible clinicians is more predictive of eventual success than almost any market-size projection.

Pull is also the cheapest thing to verify and the easiest to fake, which is why reading it well is a skill. Real pull shows up as clinicians spending their scarcest resource, time and reputation, on the product before it pays them anything. It shows up in the quality of the names, not the quantity of the logos.

Talk to the customers early, and listen

Underneath all of this sits the oldest discipline in the book. Talk to your customers early and often, and let what they tell you outweigh what you assumed. The clinicians will tell you, quickly and without mercy, whether you are solving a real problem or a convenient one. The companies that listen early build painkillers.

The ones that do not build elegant solutions to problems no one was losing sleep over.

Four questions, and the story they tell

Strip a medical AI company down and it has to answer four questions cleanly and being an AI company answers none of them. What is the pain. Who is the customer. How do you make money. And why now. The model is assumed. The story lives in those four answers.

What is the pain has to be a painkiller, an expensive problem someone with a budget feels. Who is the customer has to be specific, the clinician who pulls and the buyer who pays, which in healthcare are often not the same person. How do you make money has to trace the payment chain to a real code and a real payer. And why now has to explain what changed, in technology or regulation or the market, that makes this possible today when it was not before.

A company that answers those four crisply has a real story. A company that leads with its AUC and its architecture is answering a question that no longer matters.

Why the staircase rewards patience and rigor

The shape of the curve is the whole point. Value concentrates at the risers, the milestone events that step a company's value up, and the flat treads between them are where the work that produces the next riser actually happens. Understanding a company means valuing it by which riser is coming and how likely it is, rather than by which tread it currently stands on.

That is harder diligence on better-chosen signals, and it is exactly the rigor a field that climbs in steps demands.